Program development for enhancing adherence to antiretroviral therapy among persons living with HIV

AIDS Patient Care and STDs

Volumn 22, Issue 12, 2008, Pages 965-975

  Côté, José ^a,d   Godin, Gaston ^b   Garcia, Pilar Ramirez ^a   Gagnon, Marilou ^c   Rouleau, Genevieve ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DRUG WITHDRAWAL; HEALTH BEHAVIOR; HEALTH PRACTITIONER; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; SELF CARE; UNSPECIFIED SIDE EFFECT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BEHAVIOR THERAPY; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE; PROGRAM DEVELOPMENT; SOCIAL SUPPORT;

EID: 57449086837     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0124     Document Type: Article

References (94)

1. Osterberg L, Blaschke T. Adherence medication. N Engl J Med 2005;353:487-497.
2. Chesney M. Review: Adherence to HAART regimens. AIDS Patient Care STDs 2003;17:169-175.
3. Godin G, Côté J, Naccache H, Lambert LD, Trottier S. Predictors of adherence to antiretroviral therapy: A one year longitudinal study. AIDS Care 2005;17:493-504.
4. Wagels T, Battegay MA, Guex CA, Opravil M, Vernazza LP. Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. Swiss Med Wkly 2004;134:678-680.
5. Harrigan PR, Hogg SR, Dong YW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-347.
6. Lucas MG. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: A tangled web is woven. J Antimicrob Chemother 2005;55:413-416.
7. Paterson D, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
8. Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
9. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8.
10. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769-773.
11. Bartholomew LK, Parcel GS, Kok G. Intervention mapping: A process for developing theory. Health Educ Behav 1998;25:545-563.
12. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. Intervention Mapping: Designing Theory- and Evidence-Based Health Promotion Programs. Mountain View, CA: Mayfield Publishing Co., 2001.
13. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. Planning Health Promotion Programs: An Intervention Mapping Approach. San Francisco: Jossey-Bass, 2006.
14. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: Breakthroughs and barriers. AIDS Care 2002;14:309-318.
15. Escobar I, Campo M, Martin J, Fernandez-Shaw C, Pulido F, Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother 2003;37:775-781.
16. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13:1763-1769.
17. Kleeberger AC, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 2004;18:683-688.
18. Levine JA, Hinkin HC, Castellon AS, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2005;9:355-362.
19. Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care 2004;16:471-484.
20. Heckman DB, Catz LS, Heckman GT, Miller GJ, Kalichman CS. Adherence to antiretroviral therapy in rural persons living with HIV disease in the United States. AIDS Care 2004;16:219-230.
21. Mathews WC, Mar-Tang M, Ballard C, et al. Prevalence, predictors, and outcomes of early adherence after starting of changing antiretroviral therapy. AIDS Patient Care STDs 2002;16:157-172.
22. van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDs 2002;16:269-281.
23. Ammassari A, Trotta PM, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002;31:S123-S127.
24. Catz SL, Kelly JA, Bogart LM, Benotosh EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19:124-133.
25. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-395.
26. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: Findings from the Healthy Living Project. AIDS Patient Care STDs 2003;17:645-656.
27. Johnson OM, Chesnay AM, Goldstein BR, et al. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model. AIDS Patient Care STDs 2006;20:258-268.
28. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-228.
29. Gray J. Becoming adherent: Experiences of persons living with HIV/AIDS. J Assoc Nurses AIDS Care 2006;17:47-56.
30. Lewis PM, Colbert A, Erlen J, Meyers M. A qualitative study of persons who are 100% adherent to antiretroviral therapy. AIDS Care 2006;18:140-148.
31. Tuldra A, Ferrer MJ, Fumaz CR, et al. Monitoring adherence to HIV therapy. Arch Intern Med 1999;159:1376-1377.
32. Malcolm ES, Ng JJ, Rosen KR, Stone EV. An examination of HIV/AIDS patients who have an excellent adherence to HAART. AIDS Care 2003;55:413-416.
33. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc Sci Med 2002;54:1481-1496.
34. Pratt RJ, Robinson N, Loveday HP, et al. Adherence to antiretroviral therapy: Appropriate use of self-reporting in clinical practice. HIV Clin Trials 2001;2:146-159.
35. Remien HR, Hirky AE, Johnson OM, Weinhardt SL, Whitter S, Minh Le G. Adherence to medication treatment: A qualitative study to facilitators and barriers among a diverse sample of HIV + men and women in four U.S. cities. AIDS Behav 2003;7:61-72.
36. Adam DB, Maticka-Tyndale E, Cohen JJ. Adherence practices among people living with HIV. AIDS Care 2003;15:263-274.
37. Duong M, Piroth L, Grappin M, et al. Evaluation of the patient medication adherence questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials 2001;2:128-135.
38. Viswanathan H, Anderson R, Thomas J. Evaluation of an antiretroviral medication attitude scale and relationships between medication attitudes and medication nonadherence. AIDS Patient Care STDs 2005;19:306-314.
39. Molassiotis A, Nahas-Lopez V, Chung WY, Lam SW, Li CK, Lau TF. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS 2002;13:301-310.
40. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-269.
41. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. AIDS 2000;14:151-155.
42. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449.
43. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA panel. JAMA 2004;292:251-265.
44. d'Arminio Montforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000;14:499-507.
45. Roca B, Gómez CJ, Arnedo, A. Adherence, side effects and efficacy of Stavudine plus Lamivudine plus Nelfinavir in treatment-experienced HIV-infected patients. J Infect 2000;41:50-54.
46. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:527-536.
47. Corless BI, Nicholas KP, Davis MS, Dolan AS, McGibbon AC. Symptom status, medication adherence, and quality of life in HIV disease. J Hosp Palliat Nurs 2005;7:129-138.
48. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007;45:S14-S18.
49. Portsmouth S. D., Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: A 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005;6:185-190.
50. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence intervention: A research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 2006;41:285-297.
51. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000;12:387-398.
52. Graham NMH, Jacobson LP, Kuo V, Chmiel JS, Morgenstern H, Zucconi SL. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol 1994;47:1003-1012.
53. Mostashari F , Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:341-348.
54. Ramirez P, Côté J. Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS. J Assoc Nurses AIDS Care 2003;14:37-45.
55. Ingersoll KS , Heckman-Stone CJ. Patient-clinician relationships and treatment system effects on HIV medication adherence. AIDS Behav 2005;9:89-101.
56. Russell J, Krantz S, Neville S. The patient-provider relationship and adherence to highly active antiretroviral therapy. J Assoc Nurses AIDS Care 2004;15:40-47.
57. Johnston Roberts K. Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDs 2002;16:43-49.
58. Rosenbaum M. A model for research on self-regulation: Reducing the schism between behaviorism and general psychology. In: Eifert GH, Evans IM, eds. Unifying Behavior Therapy: Contribution of Paradigmatic Behaviorism. New York: Springer Publishing Co., 1990:126-149.
59. Côté J, Godin G. Efficacy of interventions in improving adherence to antiretroviral therapy. Int J STD AIDS 2005;16:335-343.
60. Bamberger JD , Unick J, Klein P, Fraser M, Chesney M, Katz MH. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health 2000;90:699-701.
61. Dilorio C, Resnicow K, McDonnell M, Soet J, McCarthy F, Yeager K. Using a motivational interviewing to promote adherence to antiretroviral medications: A pilot study. J Assoc Nurses AIDS Care 2003;14:52-62.
62. Holzemer LW, Bakken Henry S, Portillo JC, Miramontes H. The client adherence profiling-intervention tailoring (CAP-IT) intervention for enhancing adherence to HIV/AIDS medications: A pilot study. J Assoc Nurses AIDS Care 2000;11:36-44.
63. Malow RM, McPherson S, Klimas N, et al. Alcohol & drug abuse: Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv 1998;49:1021-1024.
64. Stenzel MS, McKenzie M, Mitty JA, Flanigan TP. Enhancing adherence to HAART: A pilot program of modified directly observed therapy. AIDS Reader 2001;11:317-319, 324-328.
65. Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. J Acquir Immune Defic Syndr 2003;34:191-194.
66. Knobel H, Carmona A, Lopez J, et al. Adherence to highly active antiretroviral treatment: impact on individualized assessment. Enferm Infecc Microbiol Clin 1999;17:78-81.
67. Chiou PY, Kuo BI, Lee MB, Chen YM, Chuang P, Lin PC. A program of symptom management for improving quality of life and drug adherence . J Adv Nurs 2006;55:169-179.
68. Levy RW, Rayner RC, Fairley KC, et al. Multidisciplinary HIV adherence intervention: a randomized study. AIDS Patient Care STDs 2004;18:728-734.
69. Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS 2005;19:807-814.
70. Williams BA, Fennie PK, Bova AC, Burgess DJ, Danvers AK, Dieckhaus DK. Home visits to improve adherence to highly active antiretroviral therapy: A randomized controlled trial. J Acquir Immune Defic Syndr 2006;42:314-321.
71. Mann T. Effects of future writing and optimism on health behaviors in HIV-infected women. Ann Behav Med 2001;23:26-33.
72. Murphy AD, Lu CM, Martin D, Hoffman D, Marelich DW. Results of a pilot intervention trial to improve antiretroviral adherence among HIV-positive patients. J Assoc Nurses AIDS Care 2002;13:57-69.
73. Rawling MK, Thompson MA, Farthing CF, et al. Impact of an educational program on efficacy and adherence with twice-daily lamivudine/zidovudine/ abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr 2003;34:174-183.
74. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: Pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000;15:841-847.
75. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medications: Life-steps and medication monitoring. Behav Res Ther 2001;39:1151-1162.
76. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995;37:261-269.
77. Gibson PG, Coughlan J, Wilson AJ, et al. Self-management education and regular practitioner review for adults with asthma. The Cochrane Library. 2000.
78. Schreurs LMG, Colland VT, Kuijer RG, de Ridder DTD, van Elderen T. Development, content, and process evaluation of a short self-management intervention in patients with chronic diseases requiring self-care behaviors. Patient Educ Couns 2003;51:133-141.
79. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2006.
80. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV infected drug users: Implications for program replication. Clin Infect Dis 2004;38:S376-387.
81. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: A preliminary report. J Urban Health 1999;76:468-480.
82. Macalino GE, Mitty JA, Bazerman LB, Singh K, McKenzie M, Flanigan T. Modified directly observed therapy for the treatment of HIV-seropositive susbtance users: Lessons learned from a pilot study. Clin Infect Dis 2004;38:S393-S397.
83. Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS. Patient-perceived barriers to antiretroviral adherence: Associations with race. AIDS Care 2002;14:607-617.
84. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000;12:377-386.
85. Wilson TE, Barron Y, Cohen M, et al. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis 2002;34:529-534.
86. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-1121.
87. Bandura A. Self-Efficacy: The Exercice of Control. New York: Freeman, 1997.
88. Petty RE, Wegener DT, Fabrigar LR. Attitudes and attitude change. Annu Rev Psychol 1997;48:609-647.
89. Petty RE, Fabrigar LR, Wegener DT. Emotional factors in attitudes and persuasion. In: Davidson RJ, Scherer KR, Goldsmith HH, eds. Handbook of Affective Sciences. Oxford: Oxford University Press, 2003:752-772.
90. Rutter D, Quine L. Changing Health Behavior. Philadelphia: Open University Press, 2002.
91. Kok G, Harterink P, Vriens P, deZwart O, Hospers HJ. The gay cruise: Developing a theory-and evidence-based internet HIV-prevention intervention. Sex Res Soc Policy 2006;3:52-67.
92. van Kesteren NMC, Kok G, Hospers HJ, Schippers J, de Wildt W. Systematic development of a self-help and motivational enhancement intervention to promote sexual health in HIV-positive men who have sex with men. AIDS Patient Care STDs 2006;20:858-875.
93. Wolfers MEG, van den Hoek C, Brug J, de Zwart O. Using intervention mapping to develop a programme to prevent sexually transmittable infections, including HIV, among heterosexual migrant men. BMC Public Health 2007;141:7.
94. Ramirez Garcia P. Évaluation d'une intervention infirmière visant la prise optimale d'un traitement antirétroviral chez des personnes vivant avec le VIH. In preparation.